Related Experiment Video
Updated: Apr 6, 2026
Reconstruct Human Retinoblastoma In Vitro
Published on: October 11, 2022
Progress in Small Molecule Therapeutics for the Treatment of Retinoblastoma
Eleanor M Pritchard, Michael A Dyer1, R Kiplin Guy2
1Department of Developmental Neurobiology, St Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA. Michael.dyer@stjude.org.
Abstract:
While mortality is low for intraocular retinoblastoma patients in the developed world who receive aggressive multimodal therapy, partial or full loss of vision occurs in approximately 50% of patients with advanced bilateral retinoblastoma. Therapies that preserve vision and reduce late effects are needed. Because clinical trials for retinoblastoma are difficult due to the young age of the patient population and relative rarity of the disease, robust preclinical testing of new therapies is critical. The last decade has seen advances towards identifying new therapies including the development of animal models of retinoblastoma for preclinical testing, progress in local drug delivery to reach intraocular targets, and improved understanding of the underlying biological mechanisms that give rise to retinoblastoma. This review discusses advances in these areas, with a focus on discovery and development of small molecules for the treatment of retinoblastoma, including novel targeted therapeutics such as inhibitors of the MDMX-p53 interaction (nutlin-3a), histone deacetylase (HDAC) inhibitors, and spleen tyrosine kinase (SYK) inhibitors.
Insights
New small molecule therapies are being developed for retinoblastoma (a rare eye cancer) to improve vision preservation. Advances in preclinical models and drug delivery are crucial for testing these novel treatments.
Area of Science:
- Ophthalmology
- Pediatric Oncology
- Pharmacology
Background:
- Retinoblastoma treatment has low mortality but high rates of vision loss in advanced cases.
- Developing new therapies is essential to preserve vision and minimize long-term effects.
- Clinical trials for retinoblastoma are challenging due to patient age and disease rarity.
Purpose of the Study:
- To review recent advances in preclinical testing for retinoblastoma therapies.
- To focus on the discovery and development of small molecule therapeutics.
- To highlight novel targeted agents for retinoblastoma treatment.
Main Methods:
- Review of recent literature on retinoblastoma preclinical research.
- Discussion of advancements in animal models for drug testing.
- Analysis of progress in local drug delivery systems for intraocular targets.
Main Results:
- Development of improved animal models for retinoblastoma research.
- Progress in targeted drug delivery to the eye.
- Identification of promising small molecule inhibitors, including MDMX-p53, HDAC, and SYK inhibitors.
Conclusions:
- Preclinical research is vital for advancing retinoblastoma treatment.
- Small molecule inhibitors show promise for vision-sparing retinoblastoma therapy.
- Targeted therapeutics offer new avenues for managing advanced retinoblastoma.
Related Concept Videos
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
01:20The Retinoblastoma Gene
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...